SKYRIZI 150 MG / 1 ML
RISANKIZUMAB : 150 MG / 1 ML · DIN 02519283 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is SKYRIZI?
SKYRIZI 150 MG / 1 ML contains RISANKIZUMAB : 150 MG / 1 ML. It is listed in the Health Canada Drug Product Database under DIN 02519283, held by ABBVIE CORPORATION, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 01-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SKYRIZI used for?
Moderate to severe plaque psoriasis; active psoriatic arthritis; moderately to severely active Crohn's disease; moderately to severely active ulcerative colitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02519283 |
|---|---|
| Brand name | SKYRIZI |
| Generic / active ingredient | RISANKIZUMAB : 150 MG / 1 ML |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 150 MG / 1 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L04AC18 RIZANKIZUMAB |
| AHFS class | 84:06.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Jun-2022 |
| Original market date | 2022-06-01 00:00:00 |
How is it administered?
Psoriasis/PsA: 150mg SC at Week 0, 4, then every 12 weeks. Crohn’s: 600mg IV at Week 0, 4, 8, then 360mg SC at Week 12 and every 8 weeks. UC: 1200mg IV at Week 0, 4, 8, then 180mg or 360mg SC every 8 weeks.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store refrigerated at 2°C to 8°C. Keep in original carton to protect from light. Do not freeze.
How is it supplied?
150mg/mL pre-filled pen or syringe; 180mg/1.2mL and 360mg/2.4mL cartridges with on-body injector; 90mg/mL pre-filled syringes (pack of 4); 600mg/10mL vials.
Contraindications
Hypersensitivity to risankizumab or to any ingredient in the formulation or component of the container.
Warnings and precautions
May increase risk of infections; do not use in patients with active TB or clinically important active infections. Serious hypersensitivity reactions (anaphylaxis) may occur. Avoid live vaccines.
What can be used instead?
Other Canadian products sharing ATC code L04AC18 RIZANKIZUMAB. 5 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SKYRIZI | 150 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02519291 |
| SKYRIZI | 180 MG / 1.2 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02552507 |
| SKYRIZI | 360 MG / 2.4 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02532093 |
| SKYRIZI | 60 MG | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02532107 |
| SKYRIZI | 75 MG / 0.83 ML | SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 02487454 |
| SKYRIZI | 90 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | APPROVED | DIN 02546922 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.